Lab21 gains cervical cancer platform with Novacyt merger
This article was originally published in Clinica
Executive Summary
UK molecular diagnostics firm Lab21 has agreed to merge with French firm Novacyt, gaining a listing on the Alternext exchange in Paris and a presence in the cervical cancer screening market in the process.